Has Brookline Capital Acquisition Corp II gone public yet?

Reports conflict. MarketBeat says its IPO priced on February 27, 2026 at $10.00 per unit for $100 million, but a stockanalysis.com page cached July 11, 2026 still describes it as going public soon with an unknown exact date, so confirmation is unresolved as of July 2026.

What sectors is Brookline Capital Acquisition Corp II targeting for a merger?

BCAC II is a Cayman Islands blank check SPAC that filed its S-1 on December 19, 2025, explicitly targeting the healthcare and defense or defense technology sectors for a future business combination.

Is Brookline Capital Acquisition Corp II profitable?

It is a non-operating blank check shell with no product or revenue, so profitability does not apply. Its only assets are IPO trust proceeds targeting $100 million gross, raised via 10,000,000 units at $10.00 each as of its December 19, 2025 S-1 filing.

Who sponsors Brookline Capital Acquisition Corp II?

The sponsor is Brookline Capital Holdings II, LLC, an affiliate of Brookline Capital Markets, a division of Arcadia Securities, LLC. The sponsor bought 3,938,294 Class B Insider Shares for $25,000 on February 10, 2025.

What happened to the predecessor SPAC before Brookline Capital Acquisition Corp II?

The original Brookline Capital Acquisition Corp (no II) closed its merger with Apexigen on July 31, 2022, but ended with only about $19 million net proceeds against a $205 million target valuation after heavy shareholder redemptions, per a September 29, 2022 SEC filing.

How risky is investing in Brookline Capital Acquisition Corp II?

It carries typical SPAC risk: a 24 month deadline from trust funding to complete a business combination or move toward liquidation, per its letter agreement filed February 3, 2026. Its IPO was already postponed once, on February 26, 2026, amid a Nasdaq sell off.

No grouping · Cayman Islands

Brookline Capital Acquisition Corp II

Blank-check shell SPAC seeking a healthcare or defense target to merge with.

Little protection left

Assessed 29 July 2026 · Evidence as of 29 July 2026

Not much stands between this business and its pressures.

On the recordSince 29 July 2026 · Checkable from around February 2028 · Every call on the record Checkpoint: 24-month deadline to complete a business combination or return trust cash to shareholders

The call

This is cash in a trust account looking for a company to become, with no business yet to protect or threaten.

Brookline Capital Acquisition Corp II is a blank-check company (a SPAC) with no business, products, or money-making operations. Right now it is just a shell holding cash, waiting to announce what company it will buy and merge with. Since nobody knows what business it will become, it is impossible to say whether it will succeed or fail in three to five years. The previous Brookline SPAC lost a lot of shareholder value when people pulled their money out before a merger closed, which is a warning sign that this new shell could follow the same path. Everything changes the moment the company announces which real business it plans to acquire, because then investors will finally know what they are actually betting on.

Why

AI pressure: None apparent. There is no product or operation for AI to disrupt, only cash in trust waiting for a deal. Could AI do the core job? Yes, likely.

Bigger players: None apparent. No operating business exists yet, so no company competes with it directly, only other SPACs chase similar targets. Could a giant copy it? Yes, easily.

What protects it. The $100M held in trust and the sponsor's ability to find and close a merger before the deadline runs out.

What would change this call

BCAC II files an 8-K announcing a definitive business combination agreement. Shows the shell has found a target and shifts evaluation to that operating company.
Shareholder redemption rate reported at the eventual business combination vote. High redemption near BCAC I's ~90% would signal repeat value destruction; low redemption would signal deal support.
24-month SPAC deadline passes without an announced merger. Would show the shell failed to find a target and faces liquidation or extension.

Key numbers

$100M gross IPO proceeds, 10,000,000 units at $10.00 (2026-02-27)
Sponsor paid $25,000 for 3,938,294 Class B shares (2025-02-10)
Predecessor BCAC I kept only ~$19M of a $205M target after redemptions (2025-12-19)

Named risks

24 month deadline to complete a business combination before facing liquidation. Severity: high
No merger target identified as of July 23, 2026, leaving the entity's future business undefined. Severity: high
Predecessor SPAC BCAC I suffered near total redemptions, closing with $19M vs a $205M target valuation. Severity: medium
IPO timing already disrupted once by a Nasdaq sell off on February 26, 2026, showing market sensitivity. Severity: medium
Crowded field of same window healthcare and defense SPACs competing for the same limited deal supply. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Churchill Capital Corp XII	losing to	Larger, more established SPAC sponsor platform active in same recent IPO window, as of July 23, 2026
Hennessy Capital Investment Corp VIII	losing to	Bigger incumbent sponsor competing for same limited deal supply, per July 23, 2026 IPO list
K2 Capital Acquisition II	contesting	Defense focused SPAC filed for $150 million offering in same week window as BCAC II, July 24, 2026
Aeon Acquisition I Corp	contesting	Announced pricing of a $125 million IPO in the same period per sponsor's own site, June 2026
Ocean Capital Acquisition Corporation	contesting	Priced a $100 million IPO around the same period as BCAC II, per sponsor site, June 2026

Questions people ask

Has Brookline Capital Acquisition Corp II gone public yet?: Reports conflict. MarketBeat says its IPO priced on February 27, 2026 at $10.00 per unit for $100 million, but a stockanalysis.com page cached July 11, 2026 still describes it as going public soon with an unknown exact date, so confirmation is unresolved as of July 2026.
What sectors is Brookline Capital Acquisition Corp II targeting for a merger?: BCAC II is a Cayman Islands blank check SPAC that filed its S-1 on December 19, 2025, explicitly targeting the healthcare and defense or defense technology sectors for a future business combination.
Is Brookline Capital Acquisition Corp II profitable?: It is a non-operating blank check shell with no product or revenue, so profitability does not apply. Its only assets are IPO trust proceeds targeting $100 million gross, raised via 10,000,000 units at $10.00 each as of its December 19, 2025 S-1 filing.
Who sponsors Brookline Capital Acquisition Corp II?: The sponsor is Brookline Capital Holdings II, LLC, an affiliate of Brookline Capital Markets, a division of Arcadia Securities, LLC. The sponsor bought 3,938,294 Class B Insider Shares for $25,000 on February 10, 2025.
What happened to the predecessor SPAC before Brookline Capital Acquisition Corp II?: The original Brookline Capital Acquisition Corp (no II) closed its merger with Apexigen on July 31, 2022, but ended with only about $19 million net proceeds against a $205 million target valuation after heavy shareholder redemptions, per a September 29, 2022 SEC filing.
How risky is investing in Brookline Capital Acquisition Corp II?: It carries typical SPAC risk: a 24 month deadline from trust funding to complete a business combination or move toward liquidation, per its letter agreement filed February 3, 2026. Its IPO was already postponed once, on February 26, 2026, amid a Nasdaq sell off.

Timeline

2026-02-27MarketBeat reports IPO priced, 10,000,000 shares at $10.00 for $100M gross (unconfirmed for BCAC II specifically)
2026-02-26IPO postponed amid Nasdaq sell off, then revived same day or next day
2026-02-23S-1/A amendment raises rights ratio to 1/8 share, adds Clear Street as IPO co-manager
2026-02-10Sponsor purchases 3,938,294 Class B Insider Shares for $25,000
2026-02-04Sponsor's total Insider Shares reach 4,583,916 after capitalizations and director transfers
2026-02-03Underwriting and letter agreements filed setting 24-month deal deadline
2025-12-19S-1 registration statement filed for $100 million IPO targeting healthcare and defense
2022-09-29Predecessor BCAC I discloses ~$19M net proceeds vs $205M target valuation post Apexigen merger
2022-07-31Predecessor BCAC I closes business combination with Apexigen, ceasing to exist as a SPAC

Revision history

29 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Optimum Communications Warner Bros. Discovery Inflection AI

More companies little protection left →

Sources